What does AXCOFARMA do?

AXCOFARMA is a pharmacy in Diepenbeek. Private Limited, started on 8 June 2007, 1 establishment.

What is the address of AXCOFARMA?

The registered office of AXCOFARMA is located at Schoolstraat 8, 3590 Diepenbeek.

Is AXCOFARMA still active?

Yes. According to the CBE (30 October 2026) AXCOFARMA is active, legal situation “Normale toestand”, started on 8 June 2007.

Is AXCOFARMA registered on Peppol?

Yes, AXCOFARMA is registered on the Peppol network with ID 0208:0889949363.

What is the enterprise number of AXCOFARMA?

The enterprise number of AXCOFARMA is BE0889949363.

When was AXCOFARMA founded?

AXCOFARMA was founded on 8 June 2007.

Who are the directors of AXCOFARMA?

According to the 2025 annual accounts, the directors of AXCOFARMA are: Axcolim N.V..

Is AXCOFARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 8 June 2007; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did AXCOFARMA make in 2025?

AXCOFARMA posted a profit after taxes of € 30,886 in financial year 2025.

What is the revenue of AXCOFARMA?

As a small company, AXCOFARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 141,281.

How much does an employee at AXCOFARMA earn?

The average wage cost per full-time employee at AXCOFARMA was € 47,600 in 2023: staff costs of € 57,080 for 1.2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

AXCOFARMA (Private Limited) - Diepenbeek - BE0889949363

Dossier AXCOFARMA, printed on 30 October 2026 from databakkes.be/en/0889949363/axcofarma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 34 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

AXCOFARMA from Diepenbeek, company number BE0889949363, closed financial year 2025 with a result of € 30,886 after tax. For that financial year AXCOFARMA recorded a gross margin of € 141,281 and equity of € 47,483. Compared with financial year 2024, the result moved from € 10,775 to € 30,886. Profitable, and profit is growing. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 18, 2026.

What it is worth Healthy

€ 47,483

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 30,886

▲ 187% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 99,451

▼ 61% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 30,886 paid out

100 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Wage cost

€ 67,496

▲ 2% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 4,284

▼ 10% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 31,667

▼ 52% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 16,847

▲ 17% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 132,600 Gross margin 2022: € 132,600 First fiscal year in the series	€ 86,417 Gross margin 2023: € 86,417 ▼ 35% vs 2022 (€ 132,600) Unfavourable step	€ 84,090 Gross margin 2024: € 84,090 ▼ 3% vs 2023 (€ 86,417) Unfavourable step	€ 141,281 Gross margin 2025: € 141,281 ▲ 68% vs 2024 (€ 84,090) Favourable step	▲ 68%
Profit after taxes	€ 77,458 Profit after taxes 2022: € 77,458 First fiscal year in the series	€ 25,805 Profit after taxes 2023: € 25,805 ▼ 67% vs 2022 (€ 77,458) Unfavourable step	€ 10,775 Profit after taxes 2024: € 10,775 ▼ 58% vs 2023 (€ 25,805) Unfavourable step	€ 30,886 Profit after taxes 2025: € 30,886 ▲ 187% vs 2024 (€ 10,775) Favourable step	▲ 187%
Equity	€ 35,903 Equity 2022: € 35,903 First fiscal year in the series	€ 36,708 Equity 2023: € 36,708 ▲ 2% vs 2022 (€ 35,903) Favourable step	€ 47,483 Equity 2024: € 47,483 ▲ 29% vs 2023 (€ 36,708) Favourable step	€ 47,483 Equity 2025: € 47,483 Unchanged (€ 47,483) Unchanged
Total debts	€ 436,704 Total debts 2022: € 436,704 First fiscal year in the series	€ 320,298 Total debts 2023: € 320,298 ▼ 27% vs 2022 (€ 436,704) Favourable step	€ 335,661 Total debts 2024: € 335,661 ▲ 5% vs 2023 (€ 320,298) Unfavourable step	€ 441,690 Total debts 2025: € 441,690 ▲ 32% vs 2024 (€ 335,661) Unfavourable step	▲ 32%
Cash	€ 359,514 Cash 2022: € 359,514 First fiscal year in the series	€ 225,420 Cash 2023: € 225,420 ▼ 37% vs 2022 (€ 359,514) Unfavourable step	€ 255,603 Cash 2024: € 255,603 ▲ 13% vs 2023 (€ 225,420) Favourable step	€ 99,451 Cash 2025: € 99,451 ▼ 61% vs 2024 (€ 255,603) Unfavourable step	▼ 61%
Land & buildings	€ 2,435 Land & buildings 2022: € 2,435 First fiscal year in the series	€ 1,610 Land & buildings 2023: € 1,610 ▼ 34% vs 2022 (€ 2,435) Unchanged	€ 784 Land & buildings 2024: € 784 ▼ 51% vs 2023 (€ 1,610) Unchanged	€ 254,329 Land & buildings 2025: € 254,329 ▲ € 253,545 vs 2024 (€ 784) Unchanged	▲ € 253,545
Retained profit	€ 23,503 Retained profit 2022: € 23,503 First fiscal year in the series	€ 24,308 Retained profit 2023: € 24,308 ▲ 3% vs 2022 (€ 23,503) Favourable step	€ 35,083 Retained profit 2024: € 35,083 ▲ 44% vs 2023 (€ 24,308) Favourable step	€ 35,083 Retained profit 2025: € 35,083 Unchanged (€ 35,083) Unchanged
Dividend	€ 77,000 Dividend 2022: € 77,000 First fiscal year in the series	€ 25,000 Dividend 2023: € 25,000 ▼ 68% vs 2022 (€ 77,000) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 25,000) Unchanged	€ 30,886 Dividend 2025: € 30,886 Unchanged (€ 0) Unchanged
Balance sheet total	€ 472,607 Balance sheet total 2022: € 472,607 First fiscal year in the series	€ 357,006 Balance sheet total 2023: € 357,006 ▼ 24% vs 2022 (€ 472,607) Unchanged	€ 383,144 Balance sheet total 2024: € 383,144 ▲ 7% vs 2023 (€ 357,006) Unchanged	€ 489,172 Balance sheet total 2025: € 489,172 ▲ 28% vs 2024 (€ 383,144) Unchanged	▲ 28%
Employees (FTE)	-	1.2 Employees (FTE) 2023: 1.2 First fiscal year in the series	-	-

Key figures of AXCOFARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to AXCOFARMA?

What happened at AXCOFARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 18, 2026 New annual accounts for financial year 2025: profit of € 30,886 (▲ 187% vs 2024). Source: NBB ↗
2010 Axcolim N.V. became a director. NBB
Jun 8, 2007 Start of the company according to the CBE. KBO
May 25, 2007 New establishment in Diepenbeek. KBO

In short

From € 77,458 profit in 2022 to € 30,886 profit in 2025.

Paid € 6,324 in corporate taxes since 2022.

Best year ever: 2022, with € 77,458 profit.

On average € 72,000 of value added per employee in 2023.

Original PDFs at the National Bank ↗

Management

Axcolim N.V.

AXCOFARMA

APOTHEEK COLLA-ACKX

Behind AXCOFARMA is Axcolim N.V.. Axcolim N.V. is also behind APOTHEEK COLLA-ACKX.

Directors

According to the 2025 annual accounts

Axcolim N.V.

Director · represented by Vivian Ackx

Also active at: APOTHEEK COLLA-ACKX

since 2010

Establishments

Establishment units

Physical locations of this company

Registered office

Schoolstraat 8

3590 Diepenbeek

2.163.642.111

Nieuwstraat 173 box 1

3590 Diepenbeek

Active since 25 May 2007

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

APOTHEEK COLLA-ACKX same network

€ 330,511 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0889.949.363

VAT number

BE 0889.949.363

Registered office

Schoolstraat 8, 3590 Diepenbeek

Names & denominations

AXCOFARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

8 June 2007

Peppol

Active · Active since 16 Oct 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

Bemiddeling in verband met exploitatie van en handel in onroerend goed

Bemiddeling bij de aankoop, verkoop en verhuur van onroerend goed

Bemiddeling bij de aankoop, verkoop en verhuur van onroerend goed voor een vast bedrag of op contractbasis

View on CBE Public ↗ Annual accounts (NBB) ↗

AXCOFARMA

Warning lights

Financials

What happened to AXCOFARMA?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions